logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Bioverativ Therapeutics Inc.


USPTO Granted Patents = 73



Trademarks = 11

Forward Citations = 240

Loading Chart...
Loading Chart...

87 inventors (with patents filed for the assignee):

goldMedal Robert T Peters (39 out of 61 patents)

silverMedal Haiyan Jiang (25 out of 30 patents)

bronzeMedal Glenn Pierce (19 out of 25 patents)

4.  Tongyao Liu (15 out of 15 patents)

5.  Susan C Low (10 out of 21 patents)

6.  Samantha Truex (10 out of 11 patents)

7.  John D Kulman (9 out of 17 patents)

8.  Alan J Bitonti (8 out of 43 patents)

9.  Jurg Sommer (8 out of 10 patents)

10.  Ekta Seth Chhabra (7 out of 7 patents)

11.  Jennifer A Dumont (7 out of 18 patents)

12.  Joe Salas (7 out of 9 patents)

13.  Adam Robert Mezo (7 out of 24 patents)

14.  Siyuan Tan (5 out of 17 patents)

15.  Daniel S Rivera (4 out of 11 patents)


Core Competencies:
Factor VIII Polypeptide Formulations
Lentiviral Vector Formulations
Gene Therapy
Chimeric Clotting Factors
Immunogenicity Reduction
Hemophilia Treatment
Recombinant Proteins
Blood Factor Monitoring
Viral Inactivation Methods
Optimized Factor IX Gene
Factor IX Fusion Proteins
Clotting Factor Assays

73 patents:

1. 12403183 - Factor VIII polypeptide formulations (2025-09-02),
2. 12403164 - Lentiviral vector formulations (2025-09-02),
3. 12371747 - Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy (2025-07-29),
4. 12364774 - Nucleic acid molecules and uses thereof for non-viral gene therapy (2025-07-22),
5. 12275970 - Optimized factor IX gene (2025-04-14),
6. 12257288 - Methods of inducing immune tolerance to clotting factors (2025-03-25),
7. 12186375 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof (2025-01-07),
8. 12173307 - Methods for the purification of viral vectors (2024-12-24),
9. 12168776 - Nucleic acid molecules and uses thereof (2024-12-17),
10. 12161696 - Methods of treating hemophilic arthropathy using chimeric clotting factors (2024-12-10),
11. 12134632 - On-column viral inactivation methods (2024-11-05),
12. 12128092 - Lyophilized factor IX formulations (2024-10-29),
13. 12030925 - Methods of treating hemophilia A (2024-07-09),
14. 11787851 - Optimized factor VIII gene (2023-10-17),
15. 11753461 - Optimized factor VIII genes (2023-09-12),
Bioverativ Therapeutics Inc. is a biotechnology company focused on discovering, developing, and commercializing innovative therapies for people with blood disorders. With a strong commitment to transforming patient care, Bioverativ specializes in hemophilia and other rare blood disorders. They strive to pioneer breakthrough treatments and improve the lives of patients worldwide. For more information, please visit their website.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

73 Patents

#16 in Waltham, MA

#267 in Massachusetts

#4,850 in US

#9,949 in the World

...
Waltham, MA, United States of America

Bioverativ Therapeutics Inc.

Forward Citations = 240

87 inventors:

goldMedal Robert T Peters (39 out of 61 patents)

silverMedal Haiyan Jiang (25 out of 30 patents)

bronzeMedal Glenn Pierce (19 out of 25 patents)

4.  Tongyao Liu (15 out of 15 patents)

5.  Susan C Low (10 out of 21 patents)

Please report any incorrect information to support@idiyas.com
Loading…